1Dalmasso, G, Cottrez, F, Imbert, V, et al. (2006) Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131, 1812–1825.
2Hempel, S, Newberry, SJ & Maher, AR (2012) Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 307, 1959–1969.
3Buts, JP, De Keyser, N & Raedemaeker, L (1994) Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res 36, 522–527.
4Buts, JP, Bernasconi, P, Vaerman, JP, et al. (1990) Stimulation of secretory Ig A and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35, 251–256.
5Pothoulakis, C (2009) Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther 15, 826–833.
6McFarland, LV (2010) Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 14, 2202–2222.
7Bartlett, JG (2002) Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346, 334–339.
8Drehobl, MA, De Salvo, MC, Lewis, DE, et al. (2005) Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 128, 2230–2237.
9McKenna, S & Evans, G (2001) Macrolides: a Canadian Infectious Disease Society position paper. Can J Infect Dis 12, 218–231.
10Leitner, JM, Graninger, W & Thalhammer, F (2010) Hepatotoxicity of antibacterials: pathomechanisms and clinical. Infection 38, 3–11.
11Olivet, J, Cowan, KH & Curt, GA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309, 1094–1104.
12Curd, CD, Manno, JE & Stewart, JJ (1985) Effects of methotrexate on intestinal transit in rats. Fundam Appl Toxicol 5, 991–996.
13Jahovic, N, Sener, G, Cevik, H, et al. (2004) Amelioration of methotrexate-induced enteritis by melatonin in rats. Cell Biochem Funct 22, 169–178.
14Buts, JP, Bernasconi, P & Craynest, MPV (1986) Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 20, 192–196.
15Blehaut, H, Massot, J & Elmer, GW (1989) Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 10, 353–364.
16Kim, YC, Lee, JH, Kim, SH, et al. (2005) Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus. Antimicrob Agents Chemother 49, 2528–2532.
17Udassin, R, Eimerl, D, Schiffman, J, et al. (1994) Epidural anesthesia accelerates the recovery of postischemic bowel motility in the rat. Anesthesiology 80, 832–836.
18Bradley, PP, Priebat, DA, Christersen, RD, et al. (1982) Measurement of cutaneous inflammation. Estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78, 206–209.
19Aykaç, G, Uysal, M, Yalçin, AS, et al. (1985) The effect of chronic ethanol ingestion on hepatic lipid peroxide, glutathione, glutathione peroxidase and glutathione transferase in rats. Toxicology 36, 71–76.
20Casini, AF, Ferrali, M, Pompella, A, et al. (1986) Lipid peroxidation and cellular damage in extrahepatic tissues of bromobenzene-intoxicated mice. Am J Pathol 123, 520–531.
21Sener, G, Eksioglu-Demiralp, E, Cetiner, M, et al. (2006) l-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol 22, 47–60.
22Peeters, TL (1993) Erythromycin and other macrolides as prokinetic agents. Gastroenterology 105, 1886–1899.
23Bortolotti, M, Mari, C, Brunelli, F, et al. (1999) Effect of intravenous clarithromycin on interdigestive gastroduodenal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Dig Dis Sci 44, 2439–2442.
24Rodrigues, AD, Roberts, EM, Mulford, DJ, et al. (1997) Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 25, 623–630.
25Pessayre, D, Tinel, M, Larrey, D, et al. (1983) Inactivation of cytochrome P-450 by a troleandomycin metabolite. Protective role of glutathione. J Pharmacol Exp Ther 224, 685–691.
26Johnston, BC, Supina, AL, Ospina, M, et al. (2007) Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database of Systematic Reviews, issue 2 CD004827.
27Duman, DG, Bor, S, Ozutemiz, O, et al. (2005) Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 17, 1357–1361.
28Peran, L, Camuesco, D, Comalada, M, et al. (2005) Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J Gastroenterol 11, 5185–5192.
29Chen, X, Kokkotou, EG, Mustafa, N, et al. (2006) Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 281, 24449–24454.
30Mumy, KL, Chen, X, Kelly, CP, et al. (2008) Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol 294, G599–G609.
31Sougioultzis, S, Simeonidis, S, Bhaskar, KR, et al. (2006) Saccharomyces boulardii produces a soluble antiinflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 343, 69–76.
32Xue, H, Sawyer, MB, Wischmeyer, PE, et al. (2011) Nutrition modulation of gastrointestinal toxicity related to cancer chemotherapy: from preclinical findings to clinical strategy. JPEN J Parenter Enteral Nutr 35, 74–90.
33Sonis, ST, Elting, LS, Keefe, DMK, et al. (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100, 1995–2025.
34Lee, SK, Kim, YW, Chi, SG, et al. (2009) The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci 54, 255–263.
35Sezer, A, Usta, U & Cicin, I (2009) The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Med Oncol 26, 350–357.
36Forestier, C, De Champs, C & Vatoux, C (2001) Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. Res Microbiol 152, 167–173.
37Isolauri, E (2001) Probiotics in human disease. Am J Clin Nutr 73, 1142S–1146S.
38Tooley, KL, Howarth, GS, Lymn, KA, et al. (2006) Oral ingestion of Streptococcus thermophilus diminishes severity of small intestinal mucositis in methotrexate treated rats. Cancer Biol Ther 5, 593–600.
39Generoso, SV, Viana, ML, Santos, RG, et al. (2011) Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii. Eur J Nutr 50, 261–269.
40Zanello, G, Meurens, F, Berri, M, et al. (2011) Saccharomyces cerevisiae decreases inflammatory responses induced by F4+ enterotoxigenic Escherichia coli in porcine intestinal epithelial cells. Vet Immunol Immunopathol 141, 133–138.
41Jawhara, S, Habib, K, Maggiotto, F, et al. (2012) Modulation of intestinal inflammation by yeasts and cell wall extracts: strain dependence and unexpected anti-inflammatory role of glucan fractions. PLoS One 7, .
42Lessard, M, Dupuis, M, Gagnon, N, et al. (2009) Administration of Pediococcus acidilactici or Saccharomyces cerevisiae boulardii modulates development of porcine mucosal immunity and reduces intestinal bacterial translocation after Escherichia coli challenge. J Anim Sci 87, 922–934.
43Akyol, S, Mas, MR, Comert, B, et al. (2003) The effect of antibiotic and probiotic combination therapy on secondary pancreatic infections and oxidative stress parameters in experimental acute necrotizing pancreatitis. Pancreas 26, 363–367.